Maxim Group Initiates Coverage On Lipella Pharmaceuticals with Buy Rating, Announces Price Target of $2
Portfolio Pulse from Benzinga Newsdesk
Maxim Group analyst Jason McCarthy has initiated coverage on Lipella Pharmaceuticals (NASDAQ:LIPO) with a Buy rating and set a price target of $2.
April 09, 2024 | 3:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Maxim Group initiated coverage on Lipella Pharmaceuticals with a Buy rating and a price target of $2.
The initiation of coverage by a reputable analyst with a Buy rating and a specific price target usually signals a positive outlook on the stock, potentially leading to increased investor interest and a positive short term price movement.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100